Beachbody Company, Inc.

BODI
Price: $3.38Market Cap: $24.7M

Investment snapshot

24%positive consensus
Scored 1d ago

Positive

4

BUY / PASS

Neutral / negative

3 / 9

NEUTRAL / FAIL

Median fair value

$20.58

+508.0% vs price

Models with upside

2 / 17

Positive margin of safety

Strongest signal

Models split on BODI at $3.38 — fair values range $2.41–$20.69

Key risk

All 8 investors flag BODI's growth

Framework analysis

VerdictMeaning
BUYPositive purchase signal: the framework's buy requirements are met.
PASSThe company clears the framework's checklist or screen, but the framework does not produce a buy signal. For valuation frameworks this often means margin of safety is missing, insufficient, or unavailable; some screen-only frameworks have no intrinsic-value BUY state.
NEUTRALNeither a positive nor negative conclusion. It does not mean to hold an existing position.
FAILThe company does not clear the framework's requirements.
RankedRanked strategies do not use PASS: selected cohort is BUY, outside the cohort is FAIL, and unranked is NEUTRAL.

Current investor scores use trailing 12-month flows and the latest balance sheet where supported. Multi-year and EPS tests retain annual history; each framework shows its financial basis below. Intrinsic values use annual financials.

MetricGraham

Defensive Value

Buffett

Quality Compounder

Lynch

GARP

Greenblatt

Magic Formula

Piotroski

F-Score

Dreman

Contrarian Value

Munger

Quality Focus

Pabrai

Dhandho Framework

Akre

Three-Legged Stool

Marks

Risk-Aware Value

Ackman

Activist Value

Templeton

Global Bargain Hunter

Sleep

Scale Economies Shared

Asness

Systematic Factors

Neff

Low-P/E Total Return

Schloss

Asset-Value Discipline

O'Shaughnessy

Systematic Factor Composite

VerdictFAILFAILFAILNot rankedPASSFAILPASSNEUTRALFAILFAILPASSNEUTRALFAILBUYFAILFAILNEUTRAL
Score
AnalysisChecking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…Checking access…
Intrinsic Value (annual)N/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/AN/A
Margin of SafetyN/A-40.5%N/AN/AN/AN/A+83.6%N/AN/AN/A+83.6%N/AN/AN/AN/AN/AN/A
Financial Basis

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Annual history · FY 2025

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30 · TTM ended 2026-09-30 vs 2025-09-30 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Qualitative assessment · Annual history · FY 2025

Latest source filing: 2026-03-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment · TTM ended 2026-09-30 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Qualitative assessment

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Market data at 2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Price history 2025-01-01–2026-11-01 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Qualitative assessment

Latest source filing: 2026-03-10

Score computed: 2026-11-14

TTM ended 2026-09-30 · Balance sheet at 2026-09-30 · Price history 2025-01-01–2026-11-01 · Annual history · FY 2025

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · TTM ended 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Annual history · FY 2025 · Balance sheet at 2026-09-30

Latest source filing: 2026-11-10

Score computed: 2026-11-14

TTM ended 2026-09-30 · Annual history · FY 2025 · Price history 2025-01-01–2026-11-01

Latest source filing: 2026-11-10

Score computed: 2026-11-14

Where It Passes

  • Valuation models67% pass✓ 2✗ 1▾

    Models split on BODI at $3.38 — fair values range $2.41–$20.69

    Buffett fair value$2.41
    ✗Buffett-40.5% margin vs $3.38
    Munger fair value$20.69
    ✓Munger+83.6% margin vs $3.38
    Ackman fair value$20.58
    ✓Ackman+83.6% margin vs $3.38

Where It Falls Short

  • Growth0% pass✗ 13▾

    All 8 investors flag BODI's growth

    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    Inventory Growth vs Revenue GrowthInv: 29.5% vs Rev: -27.6%
    ✗LynchInventory growth < Revenue growth
    EPS Growth Direction
    ✗DremanPositive over recent years
    EPS CAGR
    ✗Dreman> 5% annualized
    Positive Net Income Frequency1/7 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    3yr Median Revenue Growth-23.9%
    ✗Ackman>= 5%
    Positive EPS Growth Frequency
    ✗AckmanPositive EPS growth in >= 3 of last 5 years
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Revenue growth vs. gross and operating margin trendgross margin 61.3% -> 73.0%, operating margin -26.7% -> 2.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    5-year Revenue CAGR-21.9%
    ✗SleepCAGR > 7%
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
  • Profitability13% pass✓ 13✗ 22▾

    14 of 16 flag BODI's profitability — Graham, Buffett, Lynch +11 more

    Positive EPS (10 years)1/8 years positive
    ✗GrahamPositive EPS every year for 10 years
    EPS Growth (3-yr avg, 10-yr window)
    ✗Graham>= 33% growth
    Net Income Positive (10+ years)1/8 years positive
    ✗BuffettPositive every year for 10+ years
    ROE (up to 5-year arithmetic mean)-119.8%
    ✗Buffett> 15% arithmetic mean (app rule)
    Operating Margin (10-yr trend)2.2% (latest)
    ✗BuffettStable or rising over 10 years
    Free Cash Flow Proxy$1.4M
    ✗BuffettPositive and growing
    Earnings Variance (10-yr CoV)
    ✗BuffettCoV < 0.3
    Retained Earnings Effectiveness
    ✗Buffett$1 retained -> > $1 market value created
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    3-5 Year EPS CAGR
    ✗Lynch15-30% (Fast Grower); > 0% to pass
    ROE28.8%
    ✓Lynch> 15%
    EBIT / Enterprise Value71.0%
    ✓Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=71.0%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Net Income / Total Assets-1.95%
    ✗PiotroskiROA > 0
    ROA Change YoY-41.04% -> -1.95% (delta: +39.10%)
    ✓PiotroskiCurrent ROA > Prior ROA
    (CFO / Total Assets) vs ROACFO/Assets=14.79%, ROA=-1.95%
    ✓PiotroskiCFO/Assets > ROA
    Gross Margin Change YoY68.6% -> 73.0%
    ✓PiotroskiImproved YoY
    Pre-Tax Income / Revenue6.0%
    ✗Dreman>= 8%
    Net Income / Shareholders' Equity28.8%
    ✓Dreman> 12%
    Margin of SafetyP/B=0.8x
    ✓PabraiP/B < 1.5 or P/E < 15
    Return on Equity-149.3% (3-yr avg)
    ✗AkreROE > 20% (3-year avg)
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Positive Net Income Frequency1/7 years positive
    ✗MarksPositive net income in >= 7 of last 10 years
    Operating Income / Revenue7.0%
    ✗Ackman>= 15%
    Net Income / Shareholders Equity28.8%
    ✓Ackman>= 15%
    5-Year EPS CAGR
    ✗Templeton> 0% (5-year EPS CAGR)
    Operating Margin Trend-26.7% (2023) -> 2.2% (2025)
    ✓TempletonNon-negative operating-margin trend over 3 years
    Revenue growth vs. gross and operating margin trendgross margin 61.3% -> 73.0%, operating margin -26.7% -> 2.2%
    ✗SleepRevenue rising; gross margin flat or falling; operating margin holding
    Net income / market capitalization+49.22%; #142/6340 (top 2.2%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Gross profit / total assets+114.73%; #112/3702 (top 3.0%)
    ✓AsnessTop 30% of eligible cross-section
    Net income / positive book equity+28.76%; #476/5226 (top 9.1%)
    ✓AsnessTop 30% of eligible cross-section
    Negative 5-year standard deviation of ROA-0.1795; #4113/5884 (top 69.9%)
    ✗AsnessTop 30% of eligible cross-section
    3-5 Year Diluted EPS CAGR
    ✗Neff7%-20% annualized
    Positive Diluted-EPS Years1/7 years positive
    ✗Schloss>= 70% positive over 5-10 observed years (app rule)
  • Efficiency13% pass✓ 2✗ 9▾

    7 of 8 flag BODI's efficiency — Graham, Buffett, Greenblatt +4 more

    Current Ratio0.79
    ✗Graham>= 2.0
    ROIC (3-5 yr avg)-96.6%
    ✗Buffett> 10%
    ROIC - WACC-106.6%
    ✗BuffettPositive (WACC = 10%)
    EBIT / (NWC + Net Fixed Assets)N/A (invested capital <= 0)
    ✗Greenblatt> 25%
    Current Ratio Change YoY0.62 -> 0.74
    ✓PiotroskiIncreased YoY
    Revenue / Total Assets Change YoY2.40x -> 1.71x
    ✗PiotroskiImproved YoY
    Current Assets / Current Liabilities0.79
    ✗Dreman> 1.5
    Return on Invested Capital17.3%
    ✓Munger> 15%
    ROIC (high and growing)FY2023: ROIC=-99.2%; FY2024: ROIC=-110.5%; FY2025: ROIC=7.9%
    ✗AkreLatest 3 consecutive FYs: ROIC > 15% in each
    Reinvestment Rate x ROICN/A (non-positive net income)
    ✗AkreReinvestment Rate * ROIC > 10%
    ROIC (5-year)0/5 years above 12% (latest 7.9%)
    ✗SleepROIC > 12% in a majority of years
  • Debt & Leverage25% pass✓ 6✗ 9▾

    9 of 12 flag BODI's debt & leverage — Graham, Buffett, Lynch +6 more

    LT Debt vs Net Current AssetsLT Debt $20.2M vs NCA $-13.8M
    ✗GrahamLT Debt <= Net Current Assets
    Debt/Equity & Interest CoverageD/E: 0.54, IC: 3.4x
    ✗BuffettD/E < 0.5 AND Interest Coverage > 5x
    Total Debt / Equity0.54
    ✗Lynch< 0.33
    Cash - Long-term Debt$7.3M
    ✓LynchPositive preferred
    LT Debt / Total Assets Change5.54% -> 15.35%
    ✗PiotroskiDecreased YoY
    Current Assets / Current Liabilities0.79
    ✗Dreman> 1.5✗SchlossCurrent ratio >= 1.50x (app cutoff)
    Total Debt / Shareholders' Equity0.54
    ✓Dreman< 0.8✓Templeton< 1.0 (fixed cap; proxy for below-sector-median leverage)✓SchlossD/E < 1.00x
    Debt Levels0.54
    ✗MungerDebt/Equity < 0.5✗AkreDebt/Equity < 0.3
    Interest Coverage & Debt/EBITDAIC=3.4x, D/EBITDA=1.1x
    ✓MarksInterest Coverage > 3x; Debt/EBITDA < 4x
    Total Debt / Shareholders Equity0.54
    ✓Ackman<= 1.0
    Negative debt-to-equity (higher means less debt)-0.5411; #2550/4210 (top 60.6%)
    ✗AsnessTop 30% of eligible cross-section
  • Cash Flow30% pass✓ 5✗ 7▾

    7 of 10 flag BODI's cash flow — Buffett, Lynch, Marks +4 more

    Free Cash Flow Proxy$1.4M
    ✗BuffettPositive and growing
    FCF Positive and Growing$-7.9M
    ✗LynchPositive and growing
    Operating Cash Flow$21.8M
    ✓PiotroskiCFO > 0
    (CFO / Total Assets) vs ROACFO/Assets=14.79%, ROA=-1.95%
    ✓PiotroskiCFO/Assets > ROA
    Price / (CFO / Shares)1.1x
    ✓Dreman< 8x
    P/E or FCF YieldFCF Yield=70.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    FCF Positive3/7 years FCF positive
    ✗MarksPositive FCF in majority of recent years
    (OCF - CapEx) / Market Cap-33.3%
    ✗Ackman>= 4%
    Price / FCF per Share1.4x
    ✓Ackman<= 25
    Positive Operating Cash Flow frequency4/7 years positive
    ✗SleepPositive OCF in >= 70% of available years
    Operating Cash Flow - Capital Expenditures$-7.9M
    ✗Neff> $0 (app proxy for a strong fundamental case)
    (Operating cash flow - capex) / market capitalization-31.80%; #3680/4519 (top 81.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Valuation31% pass✓ 15✗ 13▾

    9 of 13 flag BODI's valuation — Graham, Lynch, Greenblatt +6 more

    Price / 3-yr avg EPS
    ✗Graham<= 15x
    Price-to-Book Ratio0.8x
    ✓Graham<= 1.5x
    P/E x P/B
    ✗Graham<= 22.5
    Basic earnings-growth PEG (dividends excluded)
    ✗Lynch< 1.0 (ideally < 0.5)
    EBIT / Enterprise Value71.0%
    ✓Greenblatt> 10%
    Earnings Yield + ROC AssessmentEY=71.0%, ROC=N/A (invested capital <= 0)
    ✗GreenblattBoth EY > 10% and ROC > 25%
    Price / EPS
    ✗Dreman< 12x✗Templeton< 12x (fixed ceiling; proxy for the market's cheapest 40%)
    Price / (CFO / Shares)1.1x
    ✓Dreman< 8x
    Price / Book Value per Share0.8x
    ✓Dreman< 1.2x✓Templeton< 1.5x✓SchlossP/B <= 0.80x (app cutoff)
    Valuation ReasonablenessOE Yield=6.0%
    ✓MungerP/E < 25 or Owner Earnings Yield > 5%
    P/E or FCF YieldFCF Yield=70.2%
    ✓PabraiP/E < 15 or FCF Yield > 10%
    P/B or P/E vs. Historical AverageP/B=0.8x
    ✓MarksP/E < 15 or P/B < 2.0
    Discount to Intrinsic ValueN/A (negative normalized EPS)
    ✗Marks>= 20% below intrinsic value
    Price / FCF per Share1.4x
    ✓Ackman<= 25
    Price vs. Trailing Low100% of trailing low ($3.38)
    ✓Templeton<= 120% of trailing low (certified split-adjusted live window)
    Net income / market capitalization+49.22%; #142/6340 (top 2.2%)
    ✓AsnessTop 30% of eligible cross-section✓OshaughnessyTop 10% of eligible cross-section
    Positive book equity / market capitalization+1.7111; #789/6449 (top 12.2%)
    ✓AsnessTop 30% of eligible cross-section
    Price / Diluted EPS
    ✗NeffP/E <= 15x (app proxy for a P/E 40%-60% below the market)
    (EPS CAGR % + Dividend Yield %) / P/E
    ✗Neff> 0.7 (Neff's published traditional edge)
    Price / Tangible Book Value per ShareN/A (non-positive TBVPS)
    ✗SchlossP/TBV <= 1.00x (app cutoff)
    Book Value per Share Change
    ✗SchlossLatest BVPS >= earliest BVPS over >= 3 years (app rule)
    Revenue / market capitalization+8.2749; #364/5247 (top 6.9%)
    ✓OshaughnessyTop 10% of eligible cross-section
    (Operating cash flow - capex) / market capitalization-31.80%; #3680/4519 (top 81.4%)
    ✗OshaughnessyTop 10% of eligible cross-section
    Trailing six-month price return through the evaluation date-69.06%; #5636/6202 (top 90.9%)
    ✗OshaughnessyTop 10% of eligible cross-section
  • Verdicts31% pass✓ 4✗ 9▾

    Split decision: 9 FAIL · 3 PASS · 3 NEUTRAL · 1 BUY

    Overall verdict
    ✗GrahamFAIL (2/9)✗BuffettFAIL (0/9)✗LynchFAIL (2/7)•GreenblattNot ranked✓PiotroskiPASS (F-Score 5)✗DremanFAIL (4/11)✓MungerPASS (2/4)•PabraiNEUTRAL (2/3)✗AkreFAIL (1/6)✗MarksFAIL (2/5)✓AckmanPASS (4/9)•TempletonNEUTRAL (5/8)✗SleepFAIL (1/6)✓AsnessBUY (Rank #683/2370 (Top 28.8%))✗NeffFAIL (0/6)✗SchlossFAIL (2/7)•OshaughnessyNEUTRAL (Not ranked)

Business & financials

Financial snapshot: annual FY 2025. Current investor scores may use newer quarterly data.

Company Profile

Industry: Retail
SIC Sector: Miscellaneous Retail
Size: Micro Cap($24.7M)
Revenue: $251.7M-39.9% YoY
Net Income: $2.9M+96.0% YoY

Financial Snapshot

Operating Margin2.2%
Return on Equity-9.1%
Debt / Equity0.75
Current Ratio0.74
EPS (Diluted)$-0.41
Shares Retired−2.2% / −11.7% 2y

Shareholder Return

Fiscal 2025

Issued 2.2% of shares last year, 11.7% issued over two.

Buybacks
—
Dividends
—

Company Financials

Latest TTM and quarters alongside annual years

TTM sums four consecutive quarters and uses the latest quarter-end balances. Quarter columns show three-month results; annual columns show full-year totals. Growth compares the same period a year earlier. EPS is not added for TTM; full-year ratios are blank for quarters.

The latest annual period end is unavailable. Showing the latest fiscal cycle’s quarters; quarter and annual columns may overlap. Quarterly shows the full quarter history.

MetricTTM · 2026-09-30

2025-10-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: revenue, net income, operating income, gross profit, ebit, pre tax income, interest expense, operating cash flow, depreciation amortization, capex.

Q3 FY 2026

2026-07-01 – 2026-09-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q2 FY 2026

2026-04-01 – 2026-06-30

Sources · derived quarter values

Derived from cumulative filings: operating cash flow, depreciation amortization, capex.

Q1 FY 2026

2026-01-01 – 2026-03-31

Sources
FY 2025
Sources
  • 10-K · 2026-03-10
FY 2024
Sources
  • 10-K · 2025-03-28
FY 2023
Sources
  • 10-K · 2024-03-11
FY 2022
Sources
  • 10-K · 2023-03-16
FY 2021
Sources
  • 10-K · 2022-03-01
Market Cap$24.7Mcurrent------$79.3Mest.$50.5Mest.$66.2Mest.$9.5Best.$25.1Best.
Revenue$204.6M↓28%$45.2M↓25%$49.6M↓22%$54.3M↓25%$251.7M↓40%$418.8M↓21%$527.1M↓24%$692.2M↓21%$873.6M
Operating Income$14.3M↑140%$1.3M↓74%$1.7M↑142%$3.1M↑185%$5.5M↑108%-$66.2M↑53%-$141.0M↑31%-$203.2M↑32%-$297.3M
Net Income$12.2M↑129%$3.3M↓8%$1.4M↑123%$2.3M↑140%-$2.9M↑96%-$71.6M↑53%-$152.6M↑21%-$194.2M↑15%-$228.4M
EPS (Diluted)--$0.38↓25%$0.11↑113%$0.30↑136%$-0.41↑96%$-10.51↑57%$-24.47↓3784%$-0.63↑24%$-0.83
Gross Margin72.4%↑1%70.7%↓5%72.0%71.8%↑1%73.0%↑6%68.6%↑12%61.3%↑15%53.4%↓14%62.4%
Operating Margin7.0%↑155%2.9%↓65%3.4%↑154%5.7%↑213%2.2%↑114%-15.8%↑41%-26.7%↑9%-29.3%↑14%-34.0%
ROE28.8%↑117%———-9.1%↑96%-254.3%↓38%-184.4%↓101%-91.8%↓55%-59.3%
Total Debt$22.9M↓2%$22.9M↓2%$23.6M↑1%$23.6M↑43%$23.6M↑23%$19.2M↓35%$29.6M↓28%$41.0M↑13562%$300.0K
Shareholders' Equity$42.3M↑71%$42.3M↑71%$37.2M↑84%$34.4M↑43%$31.3M↑11%$28.2M↓66%$82.8M↓61%$211.5M↓45%$385.4M
Current Ratio0.79↑21%0.79↑21%0.79↑32%0.76↑47%0.74↑20%0.62↓15%0.72↓29%1.01↓20%1.27
Debt / Equity0.54↓43%0.54↓43%0.63↓45%0.690.75↑11%0.68↑91%0.36↑84%0.19↑24789%0.00
Operating Cash Flow-$5.1M↓151%-$5.8M↓157%-$3.2M↓177%-$1.0M↓144%$21.8M↑749%$2.6M↑111%-$22.5M↑52%-$47.2M↑78%-$215.2M
Free Cash Flow-$7.9M↓236%-$6.4M↓171%-$4.0M↓265%-$1.7M↓205%$17.4M↑976%-$2.0M↑93%-$29.1M↑60%-$73.7M↑75%-$293.2M

Score history

Historical Score Timeline

Industry peers

Industry Peers

Similar companies in Retail

BODI vs Peers — Financial Grading

Revenue$251.7MBottom 25%
Net Income$2.9MBottom 25%
ROE-9.1%Bottom 25%
D/E0.75Median
Op. Margin2.2%Bottom 25%
Curr. Ratio0.74Bottom 25%
CompanyMarket CapPriceRevenueNet IncomeROED/EOp. MarginCurr. RatioGrahamBuffettLynchGreenblattPiotroskiDreman
COSTCO WHOLESALE CORP /NEWCOST$490.2B$1106.21$275.2B$8.1B27.8%0.203.8%1.032/95/96/71/3F-Score 63/11
HOME DEPOT, INC.HD$347.9B$348.69$164.7B$14.2B110.5%4.0012.7%1.063/95/93/71/3F-Score 43/11
TJX COMPANIES INC /DE/TJX$148.4B$134.37$60.4B$5.5B53.9%0.28—1.143/96/97/71/3F-Score 74/11
FASTENAL COFAST$63.3B$55.19$8.2B$1.3B31.9%0.0320.2%4.854/97/95/71/3F-Score 75/11
AUTOZONE INCAZO$52.5B$3259.70$18.9B$2.5B-73.2%-2.6119.1%0.883/96/92/71/3F-Score 64/11
KROGER COKR$41.8B$70.80$147.6B$1.0B17.1%2.681.3%0.803/94/93/70/3F-Score 73/11
WILLIAMS SONOMA INCWSM$29.9B$254.05$7.8B$1.1B52.3%—18.1%1.393/96/93/71/3F-Score 53/11
CASEYS GENERAL STORES INCCASY$26.3B$712.08$17.6B$714.4M18.1%0.62—1.013/93/92/70/3F-Score 93/11